Prescription drug · NDA
Yorvipath (Palopegteriparatide) NDC 73362-101
Palopegteriparatide 294 ug/.98mL · Injection, Solution · Subcutaneous · Ascendis Pharma, Endocrinology, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73362-101-01 | 73362010101 | 2 BOX in 1 CARTON (73362-101-01) / 1 SYRINGE in 1 BOX (73362-101-02) / 1 CARTRIDGE in 1 SYRINGE (73362-101-03) / .98 mL in 1 CARTRIDGEMarketed from Aug 9, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Yorvipath
- Generic name (nonproprietary)
- palopegteriparatide
- Active ingredients
- Palopegteriparatide — 294 ug/.98mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Ascendis Pharma, Endocrinology, Inc.NDC labeler code 73362
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 216490
- Marketing start
- Listing expires
- Other FDA classes
- Parathyroid Hormone (Chemical structure)
- Identifiers
- Product ID 73362-101_93f0f8d6-548d-4961-bf87-565892563f0eSPL ID 93f0f8d6-548d-4961-bf87-565892563f0eSPL set ID a1fa23fd-c434-443e-9a17-5750578c8602RxCUI 2693637, 2693643, 2693645, 2693646, 2693647, 2693648UNII G2N64C3385
- Pharmacologic class
- Parathyroid Hormone Analog
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N473362010101followed by a unit qualifier and the quantityPackage 73362-0101-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
YORVIPATH is indicated for the treatment of hypoparathyroidism in adults. YORVIPATH is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. ( 1 ) Limitations of Use : Not studied for acute post-surgical hypoparathyroidism. ( 1 ) Titration scheme only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment. ( 1 ) Limitations of Use YORVIPATH was not studied for acute post-surgical hypoparathyroidism. YORVIPATH's titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vita…
Excerpt only. Read the full label for complete information.
About NDC 73362-101
- What is NDC 73362-101?
- 73362-101 is the product NDC for Yorvipath (palopegteriparatide), Palopegteriparatide 294 ug/.98mL injection, solution, listed with the FDA by Ascendis Pharma, Endocrinology, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Yorvipath (Palopegteriparatide).
- What is the active ingredient?
- Palopegteriparatide.
- Who is the labeler?
- Ascendis Pharma, Endocrinology, Inc., NDC labeler code 73362. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Yorvipath?
- 2 other product NDCs are listed under this name. See all Yorvipath NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Yorvipath products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Yorvipathpalopegteriparatide | Palopegteriparatide 168 ug/.56mL | Injection, SolutionSubcutaneous | Ascendis Pharma, Endocrinology, Inc. | 73362-100 | 73362-0100-01 |
| Yorvipathpalopegteriparatide | Palopegteriparatide 420 ug/1.4mL | Injection, SolutionSubcutaneous | Ascendis Pharma, Endocrinology, Inc. | 73362-102 | 73362-0102-01 |
Other NDCs under NDA 216490
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Yorvipathpalopegteriparatide | Palopegteriparatide 168 ug/.56mL | Injection, SolutionSubcutaneous | Ascendis Pharma, Endocrinology, Inc. | 73362-100 |
| Yorvipathpalopegteriparatide | Palopegteriparatide 420 ug/1.4mL | Injection, SolutionSubcutaneous | Ascendis Pharma, Endocrinology, Inc. | 73362-102 |